MediWound (MDWD) Projected to Post Quarterly Earnings on Wednesday

MediWound (NASDAQ:MDWDGet Free Report) is expected to release its Q1 2025 earnings data before the market opens on Wednesday, May 21st. Analysts expect MediWound to post earnings of ($0.65) per share and revenue of $5.20 million for the quarter.

MediWound (NASDAQ:MDWDGet Free Report) last posted its quarterly earnings results on Wednesday, March 19th. The biopharmaceutical company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.59) by $0.23. MediWound had a negative net margin of 142.29% and a negative return on equity of 82.17%. The company had revenue of $5.84 million for the quarter, compared to analyst estimates of $5.79 million. During the same period in the prior year, the company earned ($0.19) earnings per share. On average, analysts expect MediWound to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

MediWound Stock Up 6.8%

MDWD stock opened at $19.92 on Wednesday. The company’s 50-day simple moving average is $17.10 and its 200-day simple moving average is $17.50. MediWound has a 52-week low of $12.78 and a 52-week high of $24.00. The firm has a market cap of $215.30 million, a P/E ratio of -6.87 and a beta of 0.30.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the stock. Craig Hallum assumed coverage on shares of MediWound in a report on Friday, February 28th. They issued a “buy” rating and a $39.00 price objective for the company. StockNews.com raised shares of MediWound to a “sell” rating in a research report on Friday, March 21st. HC Wainwright reissued a “buy” rating and issued a $25.00 price target on shares of MediWound in a research report on Thursday, March 20th. Finally, Alliance Global Partners assumed coverage on shares of MediWound in a research report on Friday, May 2nd. They set a “buy” rating and a $25.00 price objective for the company. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, MediWound currently has a consensus rating of “Moderate Buy” and an average target price of $29.75.

View Our Latest Analysis on MDWD

About MediWound

(Get Free Report)

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.

Further Reading

Earnings History for MediWound (NASDAQ:MDWD)

Receive News & Ratings for MediWound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound and related companies with MarketBeat.com's FREE daily email newsletter.